ERT and Bioclinica Become Clario
ERT announced that following its early Q2 merger with Bioclinica, the combined company is renamed Clario. Clario is a technology company that generates clinical evidence by fusing scientific knowledge and global scale into the endpoint technology platform.
Only Clario can deliver Trial Anywhere, the ability to execute decentralized, hybrid and site-based clinical trials by deploying technology while maintaining the precision and reliability of evidence.
Since 1990, Clario has completed more than 19,000 clinical trials and contributed to 870 regulatory approvals. Between 2019 and 2020 alone, Clario supported 70% of all Federal and Drug Administration (FDA) approvals.
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- How the NIMBLE Study Supported Adherence With Quarterly Dosing of Cemdisiran
September 18th 2025
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025